RedHill Biopharma (RDHL)
NASDAQ:RDHL
Top Page
RedHill Biopharma
(NASDAQ:RDHL)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.00
▼(-16.67% Downside)
Action:UpgradedDate:01/06/26
Score is held down primarily by weak financial performance (ongoing losses, negative equity, and negative operating/free cash flow). Technicals provide a partial offset with improving short-term trend and momentum, but longer-term trend and MACD remain unsupportive. Valuation impact is neutral due to missing P/E and dividend yield.
Positive Factors
RHB-102 development via FDA 505(b)(2) for GLP-1 GI side effects
Pursuing RHB-102 under 505(b)(2) targets GI side effects of GLP-1/GIP therapies, a structural market need. A successful approval could reduce GLP-1 discontinuation, broaden commercial partners, and provide faster, lower‑risk regulatory path and sustainable revenue streams over the medium term.
Negative Factors
Negative equity and prior high leverage
Persistent negative equity and historically high leverage constrain financial flexibility, raise refinancing and covenant risk, and limit capacity to invest in launches or trials. Such structural balance‑sheet weakness increases vulnerability to adverse outcomes and raises long‑term financing costs.
Read all positive and negative factors
Positive Factors
Negative Factors
RHB-102 development via FDA 505(b)(2) for GLP-1 GI side effects
Pursuing RHB-102 under 505(b)(2) targets GI side effects of GLP-1/GIP therapies, a structural market need. A successful approval could reduce GLP-1 discontinuation, broaden commercial partners, and provide faster, lower‑risk regulatory path and sustainable revenue streams over the medium term.
Read all positive factors
RedHill Biopharma (RDHL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.23M
Dividend YieldN/A
Average Volume (3M)1.98M
Price to Earnings (P/E)―
Beta (1Y)1.51
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees35
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,112,885
10 Day Avg. Volume104,605
30 Day Avg. Volume1,981,143
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.27
Price to Sales (P/S)1.90
P/FCF Ratio-1.63
Enterprise Value/Market Cap0.03
Enterprise Value/Revenue0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)$50.60M
RedHill Biopharma Business Overview & Revenue Model
Company Description
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal diseases and cancer. The company operates primarily in the biopharmaceutical sector, with...
How the Company Makes Money
RedHill Biopharma generates revenue through a combination of product sales, licensing agreements, and partnerships. The company's key revenue streams come from the commercialization of its proprietary drug products, which are sold to healthcare pr...
RedHill Biopharma Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
30
Negative
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.55M | 8.04M | 6.53M | 61.80M | 85.76M | 64.36M |
| Gross Profit | 6.16M | 4.85M | 3.07M | 28.46M | 36.35M | 27.47M |
| EBITDA | -7.91M | -7.59M | 26.27M | -22.18M | -63.03M | -54.98M |
| Net Income | -9.31M | -8.27M | 23.92M | -71.67M | -97.74M | -76.17M |
Balance Sheet | ||||||
| Total Assets | 18.38M | 18.04M | 23.05M | 158.87M | 181.19M | 180.24M |
| Cash, Cash Equivalents and Short-Term Investments | 2.87M | 4.62M | 6.36M | 19.98M | 38.00M | 29.79M |
| Total Debt | 214.00K | 356.00K | 1.17M | 122.69M | 87.81M | 86.90M |
| Total Liabilities | 22.79M | 22.73M | 20.98M | 207.27M | 172.31M | 166.38M |
| Stockholders Equity | -4.41M | -4.68M | 2.07M | -48.40M | 8.88M | 13.86M |
Cash Flow | ||||||
| Free Cash Flow | -8.21M | -9.38M | -35.83M | -29.38M | -65.16M | -102.35M |
| Operating Cash Flow | -8.20M | -9.37M | -35.82M | -29.18M | -65.05M | -48.58M |
| Investing Cash Flow | -12.00K | -9.00K | 3.99K | 8.30M | -8.14M | -35.65M |
| Financing Cash Flow | 3.78M | 8.42M | 21.38M | 11.45M | 73.46M | 84.37M |
RedHill Biopharma Technical Analysis
Negative
1.20
Price Trends
0.95
Negative
1.07
Negative
1.35
Negative
Market Momentum
-0.05
Negative
40.45
Neutral
58.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDHL, the sentiment is Negative. The current price of 1.2 is above the 20-day moving average (MA) of 0.83, above the 50-day MA of 0.95, and below the 200-day MA of 1.35, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 40.45 is Neutral, neither overbought nor oversold. The STOCH value of 58.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RDHL.
RedHill Biopharma Risk Analysis
RedHill Biopharma disclosed 86 risk factors in its most recent earnings report. RedHill Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
RedHill Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $4.23M | -0.42 | ― | ― | ― | ― | |
46 Neutral | $1.66M | -1.53 | 2.66% | ― | -27.81% | ― | |
45 Neutral | $26.54M | ― | -43.00% | ― | -26.92% | 69.90% | |
45 Neutral | $4.17M | -1.90 | -85.94% | ― | 25.02% | 55.11% | |
42 Neutral | $2.03M | -0.43 | ― | ― | ― | ― | |
| ― | $4.05M | -0.25 | -9999.00% | ― | ― | 79.31% |
* Healthcare Sector Average
RDHL
RedHill Biopharma
0.83
-1.58
-65.52%
CPHI
China Pharma Holdings
0.66
-0.75
-53.55%
SNOA
Sonoma Pharmaceuticals
2.41
0.12
5.24%
PRFX
PainReform
2.41
-7.99
-76.83%
UPC
Universe Pharmaceuticals
2.95
-0.57
-16.19%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
0.73
-8.43
-92.08%
RedHill Biopharma Corporate Events
RedHill Biopharma Calls March 5 Extraordinary Meeting to Approve RSU Grants and Share Capital Increase
Jan 27, 2026
On January 27, 2026, RedHill Biopharma filed a Form 6‑K announcing an Extraordinary General Meeting of Shareholders to be held on March 5, 2026, in Tel Aviv. Shareholders and ADS holders of record as of January 23, 2026, will vote on four ke...
RedHill Biopharma Calls March 5, 2026 Extraordinary Meeting to Approve RSU Grants and Share Capital Increase
Jan 22, 2026
On January 22, 2026, RedHill Biopharma filed a Form 6-K announcing an Extraordinary General Meeting of Shareholders to be held on March 5, 2026, in Tel Aviv. The meeting will ask shareholders to approve grants of restricted share units tied to ADS...
RedHill Biopharma Advances RHB-102 in GI Indications and GLP-1 Therapy Support
Jan 5, 2026
On January 5, 2026, RedHill Biopharma announced further development progress for its proprietary once-daily extended-release ondansetron formulation RHB-102 (Bekinda) across multiple gastrointestinal indications, including a planned Phase 2 proof-...
RedHill Biopharma Files Pro Forma Financials After Talicia Joint Venture Deal With Cumberland
Dec 31, 2025
On October 17, 2025, RedHill Biopharma completed a strategic transaction with Cumberland Pharmaceuticals involving Talicia®, its proprietary drug, by selling a 30% equity stake in newly formed Talicia Holdings Inc. (THI), which holds global r...
RedHill Biopharma Secures Up to $25 Million Standby Equity Facility with YA II PN
Dec 23, 2025
On December 19, 2025, RedHill Biopharma entered into a Standby Equity Purchase Agreement with YA II PN, Ltd., giving the company, over a 36‑month period from that date, the discretionary right to sell up to $25 million of its ADSs to the inv...
RedHill Biopharma’s Opaganib Shows Promise in Combating CLL Resistance
Dec 15, 2025
On December 15, 2025, RedHill Biopharma announced positive in vivo results for opaganib, showing its potential to reduce Chronic Lymphocytic Leukemia (CLL) cells by 50% when combined with venetoclax, a key CLL therapy. This development highlights ...
RedHill Biopharma Regains Nasdaq Compliance
Dec 1, 2025
RedHill Biopharma announced on December 1, 2025, that it successfully regained compliance with Nasdaq’s stockholders’ equity requirement as of November 26, 2025. This achievement supports RedHill’s strategic initiatives for 2025,...
RedHill Biopharma Expands Offering of American Depositary Shares
Nov 26, 2025
On November 26, 2025, RedHill Biopharma Ltd. announced an increase in the maximum aggregate offering amount of its American Depositary Shares under an At The Market Offering Agreement with H.C. Wainwright Co., LLC. This strategic move is expected...
RedHill Biopharma Secures $10.5 Million Judgment Win
Nov 4, 2025
RedHill Biopharma announced that the New York Supreme Court’s judgment in favor of the company against Kukbo Co. Ltd is now final and enforceable, with no further appeals possible. The court awarded RedHill over $10.5 million, including $8.6...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.